Characteristics associated with discussions of wearable devices during primary care visits include female sex, higher income, and obesity, showed new study.
Getting patients to engage with educational social media postings can be tricky for clinicians. Here, a young clinician shares how consistent yet fun content can help.
DiabetesWise Pro founder highlights the 3 most beneficial website features to help clinicians compare all the available CGMs, delivery systems, AIDs, and smart pens.
Apple recently announced a new software release that will allow Apple Watch users access to health care-focused features and apps.
ADA 2022: Use of flash continuous glucose monitoring in T2D patients not on insulin also reduced HbA1c and glycemic variability, a new study finds.
ADA 2022: Large national study found that CGM use had a positive effect on glycemic control and acute complications in T2D in the Veterans Health Administration.
ADA 2022. Tirzepatide was associated with significantly greater TIR, many fewer episodes of hypoglycemia, and less glycemic excursion vs insulin degludec in SURPASS-3 CGM.
ADA 2022: Primary care patients with T2D and HbA1c >7.5% achieved as much as a 1.5% drop in HbA1c after initiating real time continuous glucose monitoring.
ADA 2022: Patients with T2D who received a treatment intervention powered by artificial intelligence achieved a remission rate of more than 80%.
DiabetesWise Pro lets clinicians compare diabetes devices for a specific patient and provides the steps for ordering the device based on insurance type.